These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
22. Protein phosphatase 1 nuclear targeting subunit is a hypoxia inducible gene: its role in post-translational modification of p53 and MDM2. Lee SJ; Lim CJ; Min JK; Lee JK; Kim YM; Lee JY; Won MH; Kwon YG Cell Death Differ; 2007 Jun; 14(6):1106-16. PubMed ID: 17318220 [TBL] [Abstract][Full Text] [Related]
23. Preclinical Efficacy of the MDM2 Inhibitor RG7112 in MDM2-Amplified and TP53 Wild-type Glioblastomas. Verreault M; Schmitt C; Goldwirt L; Pelton K; Haidar S; Levasseur C; Guehennec J; Knoff D; Labussière M; Marie Y; Ligon AH; Mokhtari K; Hoang-Xuan K; Sanson M; Alexander BM; Wen PY; Delattre JY; Ligon KL; Idbaih A Clin Cancer Res; 2016 Mar; 22(5):1185-96. PubMed ID: 26482041 [TBL] [Abstract][Full Text] [Related]
24. Novel predictive epigenetic signature for temozolomide in non-G-CIMP glioblastomas. Yin AA; He YL; Etcheverry A; Liu YH; Aubry M; Barnholtz-Sloan J; Liu BL; Mosser J; Lu ZF; Zhang X Clin Epigenetics; 2019 May; 11(1):76. PubMed ID: 31088577 [TBL] [Abstract][Full Text] [Related]
25. The SIAH1-HIPK2-p53ser46 Damage Response Pathway is Involved in Temozolomide-Induced Glioblastoma Cell Death. He Y; Roos WP; Wu Q; Hofmann TG; Kaina B Mol Cancer Res; 2019 May; 17(5):1129-1141. PubMed ID: 30796178 [TBL] [Abstract][Full Text] [Related]
26. Exosomal transfer of miR-151a enhances chemosensitivity to temozolomide in drug-resistant glioblastoma. Zeng A; Wei Z; Yan W; Yin J; Huang X; Zhou X; Li R; Shen F; Wu W; Wang X; You Y Cancer Lett; 2018 Nov; 436():10-21. PubMed ID: 30102952 [TBL] [Abstract][Full Text] [Related]
27. Ablation of Cancer Stem Cells by Therapeutic Inhibition of the MDM2-p53 Interaction in Mucoepidermoid Carcinoma. Andrews A; Warner K; Rodriguez-Ramirez C; Pearson AT; Nör F; Zhang Z; Kerk S; Kulkarni A; Helman JI; Brenner JC; Wicha MS; Wang S; Nör JE Clin Cancer Res; 2019 Mar; 25(5):1588-1600. PubMed ID: 30498096 [TBL] [Abstract][Full Text] [Related]
28. FOXN3 inhibits cell proliferation and invasion via modulating the AKT/MDM2/p53 axis in human glioma. Wang C; Tu H; Yang L; Ma C; Hu J; Luo J; Wang H Aging (Albany NY); 2021 Sep; 13(17):21587-21598. PubMed ID: 34511432 [TBL] [Abstract][Full Text] [Related]
29. MDM2 inhibition-mediated autophagy contributes to the pro-apoptotic effect of berberine in p53-null leukemic cells. Liu J; Zhu Z; Liu Y; Wei L; Li B; Mao F; Zhang J; Wang Y; Liu Y Life Sci; 2020 Feb; 242():117228. PubMed ID: 31881227 [TBL] [Abstract][Full Text] [Related]
30. YB-1 modulates the drug resistance of glioma cells by activation of MDM2/p53 pathway. Tong H; Zhao K; Zhang J; Zhu J; Xiao J Drug Des Devel Ther; 2019; 13():317-326. PubMed ID: 30679904 [TBL] [Abstract][Full Text] [Related]
31. Oroxylin A promotes PTEN-mediated negative regulation of MDM2 transcription via SIRT3-mediated deacetylation to stabilize p53 and inhibit glycolysis in wt-p53 cancer cells. Zhao K; Zhou Y; Qiao C; Ni T; Li Z; Wang X; Guo Q; Lu N; Wei L J Hematol Oncol; 2015 Apr; 8():41. PubMed ID: 25902914 [TBL] [Abstract][Full Text] [Related]
32. Toosendanin Exerts an Anti-Cancer Effect in Glioblastoma by Inducing Estrogen Receptor β- and p53-Mediated Apoptosis. Cao L; Qu D; Wang H; Zhang S; Jia C; Shi Z; Wang Z; Zhang J; Ma J Int J Mol Sci; 2016 Nov; 17(11):. PubMed ID: 27869737 [TBL] [Abstract][Full Text] [Related]
33. MDM2 is a potential therapeutic target and prognostic factor for ovarian clear cell carcinomas with wild type TP53. Makii C; Oda K; Ikeda Y; Sone K; Hasegawa K; Uehara Y; Nishijima A; Asada K; Koso T; Fukuda T; Inaba K; Oki S; Machino H; Kojima M; Kashiyama T; Mori-Uchino M; Arimoto T; Wada-Hiraike O; Kawana K; Yano T; Fujiwara K; Aburatani H; Osuga Y; Fujii T Oncotarget; 2016 Nov; 7(46):75328-75338. PubMed ID: 27659536 [TBL] [Abstract][Full Text] [Related]
34. Negative regulation of p53 by the long isoform of ErbB3 binding protein Ebp1 in brain tumors. Kim CK; Nguyen TL; Joo KM; Nam DH; Park J; Lee KH; Cho SW; Ahn JY Cancer Res; 2010 Dec; 70(23):9730-41. PubMed ID: 21098709 [TBL] [Abstract][Full Text] [Related]
35. GADD45A plays a protective role against temozolomide treatment in glioblastoma cells. Wang HH; Chang TY; Lin WC; Wei KC; Shin JW Sci Rep; 2017 Aug; 7(1):8814. PubMed ID: 28821714 [TBL] [Abstract][Full Text] [Related]
36. Long lasting MDM2/Translocator protein modulator: a new strategy for irreversible apoptosis of human glioblastoma cells. Daniele S; Barresi E; Zappelli E; Marinelli L; Novellino E; Da Settimo F; Taliani S; Trincavelli ML; Martini C Oncotarget; 2016 Feb; 7(7):7866-84. PubMed ID: 26761214 [TBL] [Abstract][Full Text] [Related]
37. Co-transduction of ribosomal protein L23 enhances the therapeutic efficacy of adenoviral-mediated p53 gene transfer in human gastric cancer. Zhang YF; Zhang BC; Zhang AR; Wu TT; Liu J; Yu LF; Wang WX; Gao JF; Fang DC; Rao ZG Oncol Rep; 2013 Oct; 30(4):1989-95. PubMed ID: 23933826 [TBL] [Abstract][Full Text] [Related]
38. HADHA promotes glioma progression by accelerating MDM2-mediated p53 ubiquitination. Chen R; Chen H; Hu C Cancer Gene Ther; 2024 Sep; 31(9):1380-1389. PubMed ID: 39039194 [TBL] [Abstract][Full Text] [Related]
39. The enhancement of stability of p53 in MTBP induced p53-MDM2 regulatory network. Alam MJ; Fatima N; Devi GR; Ravins ; Singh RK Biosystems; 2012 Nov; 110(2):74-83. PubMed ID: 23059707 [TBL] [Abstract][Full Text] [Related]
40. Overexpression of SCYL1-BP1 stabilizes functional p53 by suppressing MDM2-mediated ubiquitination. Yan J; Di Y; Shi H; Rao H; Huo K FEBS Lett; 2010 Oct; 584(20):4319-24. PubMed ID: 20849854 [TBL] [Abstract][Full Text] [Related] [Previous] [Next] [New Search]